PERFUSE: Thirty Years of Clinical Research Leadership

BIDMC's key role in clinical cardiovascular research includes oversight of PERFUSE, a leading academic research organization providing investigators worldwide with comprehensive management and services for clinical trials.


C. Michael Gibson, MD
C. Michael Gibson, MD

PERFUSE is an Academic Research Organization founded by BIDMC interventional cardiologist C. Michael Gibson, MD. Gibson has led PERFUSE for more than 30 years, during which time he has been principal investigator of or led core services for more than 120 clinical trials, the results of which have been published in leading journals such as the New England Journal of Medicine.


PERFUSE offers a full line of trial management, social media portals, CEC, DSMB, data management and core lab services for Phase 1-4 trials worldwide. Under Gibson's direction, PERFUSE created the master database that unified data from over 25 years of TIMI studies (TIMI 1-50) in nearly 100,000 patients and coordinated data analyses for the TIMI study group and functioned as the TIMI Data Coordinating Center which he founded and directed.

Gibson has led Phase 1-4 clinical trials, and cardiology mega-trials of over 15,000 patients which eventuate in international approval of drugs like prasugrel, rivaroxaban and betrixaban. Gibson invented measures of coronary blood flow that are widely used today (the TIMI frame count, the TIMI myocardial perfusion grade). Gibson was named one of the world's most influential scientific minds of the past decade in 2014 by Thomson Reuters.

Dr. Gibson's Harvard Catalyst Profile